Nonacog beta pegol, Recombinant coagulation factor IX

Specification

• Cat#: THP-0214
• Product Name: Nonacog beta pegol, Recombinant coagulation factor IX
• Cas No: 1175512-71-6
• Description: The product is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG are cleaved to leave the activated factor IX (Factor IXa).
• Sequences: Not Available
• Molecular Weight: Not Available
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Endotoxin: <0.001 EU per 1 μg of the peptide by the LAL method
• Application: The product is indicated for the use in adults and children with hemophilia B for control and prevention of bleeding episodes, routine prophylaxis and perioperative management. In the EMA approval, it is also indicated for on-demand treatment of bleeding episodes. Hemophilia B is characterized by a deficiency in the coagulation factor IX which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing. Hemophilia B patients present more frequent bleeding episodes during childhood and adolescence than in adulthood.

Pharmaceutical Information

• Pharmaceutical Application: Nonacog beta pegol
• Targets: Target 1. Coagulation factor VII; Target 2. Coagulation factor VIII; Target 3. Coagulation factor X.